|
|
Substance Name: Fludarabine phosphate [USAN:USP:BAN]
RN: 75607-67-9
UNII: 1X9VK9O1SC
InChIKey: GIUYCYHIANZCFB-FJFJXFQQSA-N
Molecular Formula
- C10-H13-F-N5-O7-P
Molecular Weight
- 365.2127
Classification Codes
- Antimetabolites
- Antimetabolites, Antineoplastic
- Antineoplastic
- Antineoplastic Agents
- Drug / Therapeutic Agent
- Human Data
- Immunologic Factors
- Immunosuppressive Agents
- Noxae
* denotes mobile formatted website
Links to Resources
NLM Resources (File Locators)
Other Resources (Internet Locators)
Search for this InChIKey on the Web
Names and Synonyms
Name of Substance
- Fludarabine phosphate
- Fludarabine phosphate [USAN:USP:BAN]
Synonyms
- 2-Fluoro-9-(5-O-phosphono-beta-D-arabinofuranosyl)-9H-purin-6-amine
- 2-Fluoro-ARA AMP
- 2-Fluoroadenine arabinoside 5'-monophosphate
- 9-beta-Arabinofuranosyl-2-fluoroadenine-5'-phosphate
- 9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
- 9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphate
- FAMP
- Fludara
- Fludarabine 5'-monophosphate
- Fludarabine phosphate
- NSC 312887
- NSC 328002
- NSC-312887
- Oforta
- UNII-1X9VK9O1SC
Systematic Name
- 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-beta-D-arabinofuranosyl)-
Registry Numbers
CAS Registry Number
- 75607-67-9
FDA UNII
- 1X9VK9O1SC
System Generated Number
- 0075607679
Structure Descriptors
InChI
InChI=1S/C10H13FN5O7P/c11-10-14-7(12)4-8(15-10)16(2-13-4)9-6(18)5(17)3(23-9)1-22-24(19,20)21/h2-3,5-6,9,17-18H,1H2,(H2,12,14,15)(H2,19,20,21)/t3-,5-,6+,9-/m1/s1InChIKey
GIUYCYHIANZCFB-FJFJXFQQSA-NSmiles
Nc1nc(F)Toxicity
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
child | TDLo | intravenous | 18750mg/kg/5D (18750mg/kg) | BRAIN AND COVERINGS: ENCEPHALITIS SENSE ORGANS AND SPECIAL SENSES: VISUAL FIELD CHANGES: EYE | Cancer Treatment Reports. Vol. 70, Pg. 1225, 1986. |
man | TDLo | intravenous | 11655mg/kg/5D (11655mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE SENSE ORGANS AND SPECIAL SENSES: VISUAL FIELD CHANGES: EYE | Cancer Treatment Reports. Vol. 70, Pg. 1449, 1986. |
man | TDLo | intravenous | 17760mg/kg/5D (17760mg/kg) | BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS" BEHAVIORAL: COMA BRAIN AND COVERINGS: DEMYELINATION | Cancer Treatment Reports. Vol. 70, Pg. 1225, 1986. |
mouse | LD50 | intravenous | 1236mg/kg (1236mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) | National Technical Information Service. Vol. PB83-195685, |
women | LDLo | intravenous | 14245mg/kg/5D (14245mg/kg) | SKIN AND APPENDAGES (SKIN): SWEATING: OTHER SENSE ORGANS AND SPECIAL SENSES: OTHER: EYE BEHAVIORAL: EXCITEMENT | Cancer Treatment Reports. Vol. 70, Pg. 1449, 1986. |
women | TDLo | intravenous | 23125mg/kg/5D (23125mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BRAIN AND COVERINGS: ENCEPHALITIS SENSE ORGANS AND SPECIAL SENSES: VISUAL FIELD CHANGES: EYE | Cancer Treatment Reports. Vol. 70, Pg. 1225, 1986. |